117 related articles for article (PubMed ID: 27094354)
1. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.
Scaggiante B; Farra R; Dapas B; Baj G; Pozzato G; Grassi M; Zanconati F; Grassi G
Int J Pharm; 2016 Jun; 506(1-2):268-79. PubMed ID: 27094354
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
[TBL] [Abstract][Full Text] [Related]
3. The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade.
Grassi G; Scaggiante B; Farra R; Dapas B; Agostini F; Baiz D; Rosso N; Tiribelli C
Biochimie; 2007 Dec; 89(12):1544-52. PubMed ID: 17825975
[TBL] [Abstract][Full Text] [Related]
4. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing.
Tonon F; Zennaro C; Dapas B; Carraro M; Mariotti M; Grassi G
Int J Pharm; 2016 Dec; 515(1-2):583-591. PubMed ID: 27989824
[TBL] [Abstract][Full Text] [Related]
5. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAs.
Farra R; Scaggiante B; Guerra C; Pozzato G; Grassi M; Zanconati F; Perrone F; Ferrari C; Trotta F; Grassi G; Dapas B
Int J Pharm; 2017 Jun; 525(2):367-376. PubMed ID: 28229942
[TBL] [Abstract][Full Text] [Related]
7. Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6.
Farra R; Dapas B; Pozzato G; Giansante C; Heidenreich O; Uxa L; Zennaro C; Guarnieri G; Grassi G
Biochimie; 2010 May; 92(5):455-63. PubMed ID: 20144681
[TBL] [Abstract][Full Text] [Related]
8. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
10. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
Lou G; Song X; Yang F; Wu S; Wang J; Chen Z; Liu Y
J Hematol Oncol; 2015 Oct; 8():122. PubMed ID: 26514126
[TBL] [Abstract][Full Text] [Related]
11. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma.
Boulin M; Guiu S; Chauffert B; Aho S; Cercueil JP; Ghiringhelli F; Krause D; Fagnoni P; Hillon P; Bedenne L; Guiu B
Anticancer Drugs; 2011 Sep; 22(8):741-8. PubMed ID: 21487286
[TBL] [Abstract][Full Text] [Related]
12. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
13. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
14. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
15. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
16. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic elongation factor-1α 2 knockdown inhibits hepatocarcinogenesis by suppressing PI3K/Akt/NF-κB signaling.
Qiu FN; Huang Y; Chen DY; Li F; Wu YA; Wu WB; Huang XL
World J Gastroenterol; 2016 Apr; 22(16):4226-37. PubMed ID: 27122673
[TBL] [Abstract][Full Text] [Related]
19. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy.
Liu YM; Xia Y; Dai W; Han HY; Dong YX; Cai J; Zeng X; Luo FY; Yang T; Li YZ; Chen J; Guan J
BMC Cancer; 2014 Nov; 14():889. PubMed ID: 25429777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
